AstraZeneca offloads RSV drug rights to Sobi for $1.5B by Arlene Weintraub Tuesday, November 13, 2018 Critics have blasted AstraZeneca’s rummage-sale strategy as unsustainable, but CEO Pascal Soriot says it's vital for bottom-line growth.
